September was Pain Awareness Month, and Stimwave Technologies announced last month that they are launching a new clinical trial for treatment of neuropathic pain. Nerve stimulation is considered a well-established treatment for neuropathic pain. However, many patients have pain that is difficult to target, so traditional equipment has not been very successful with patients. This study will compare the commercially available spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) therapy versus sham (device off state) in a trial in the United States.
The study’s spokesperson explained, “I look forward to conducting this prospective study to generate level 1 evidence for the therapy and to widen the awareness of this novel, drug free, micro-technology option for patients suffering from the debilitating effects of peripheral neuropathy.”
“Stimwave has the first FDA cleared wireless Freedom Stimulator devices for SCS and PNS. These devices are the world’s first wireless, fully programmable, stimulators for pain management and represent a life-changing technological breakthrough for the more than 90- million people in the USA who endure daily chronic back and leg pain.”
*Please note: spinal cord stimulation is a very invasive treatment approach. NATX shares this article with you for educational purposes, and as always, we encourage you to consult your doctor before considering any new treatment options.